Search clinical trials for: fluticasone propionate plus salmeterol xinafoate combination

Total 294 results

Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. ADVAIR DISKUS® in Healthy Volunteers (BREATH-PK500)

Bioequivalence

Greece
GlaxoSmithKline

Completed

A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma

Asthma

United States, Argentina, Philippines, Canada, Brazil
Mylan Pharma UK Ltd.

Completed

MGR001 / Advair Diskus Local Equivalence Study in Asthma

Asthma

United States
GlaxoSmithKline

Completed

ROTAHALER Device Optimization Study

Asthma

Australia
GlaxoSmithKline

Completed

Use of Fluticasone Propionate/Salmeterol Combination Post Emergency Department Visit

Asthma
Oriel Therapeutics

Completed

Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma

Asthma

United States
GlaxoSmithKline

Withdrawn

Shortness Of Breath Questionnaire Validation Study

Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline

Withdrawn

A Study in Patients With Moderate Asthma to Compare Pharmacokinetics and Pharmacodynamic Effects of Fluticasone Propionate and Salmeterol Delivered Via the ROTAHALER® Inhaler Relative to the DISKUS® Inhaler

Asthma
Chiesi Farmaceutici S.p.A.

Completed

EFFICACY AND TOLERABILITY OF BECLOMETHASONE DIPROPIONATE 100 µg + FORMOTEROL 6 µg pMDI VIA HFA-134a vs. FLUTICASONE 125 µg + SALMETEROL 25 µg pMDI

Bronchial Asthma

Poland, Ukraine
GlaxoSmithKline

Completed

SERETIDE 100/50 bd (Twice Daily) Versus FLIXOTIDE 100 bd As Initial Maintenance Therapy In Moderate Asthma In Adults

Asthma
GlaxoSmithKline

Completed

Clinical Assessment Of GW815SF HFA MDI In Pediatric Patients With Bronchial Asthma

Bronchial Asthma

Japan
GlaxoSmithKline

Completed

Clinical Evaluation Of GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)

Pulmonary Disease, Chronic Obstructive

Japan
GlaxoSmithKline

Completed

Chronic Obstructive Pulmonary Disease Endpoints Study

Pulmonary Disease, Chronic Obstructive

Russian Federation, United States, Estonia, Chile
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With Asthma

Asthma

United States
Dey

Completed

A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United States
GlaxoSmithKline

Completed

Study Of Asthma And Genetics In Patients To Be Treated With Fluticasone Propionate/Salmeterol Or Salmeterol Xinafoate

Asthma

United States, Peru, Kenya, Puerto Rico
GlaxoSmithKline

Completed

Treatment Of Partial Reversible Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Netherlands
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Salmeterol Xinafoate and Fluticasone Propinate Powder for Inhalation for Asthma

Asthma

China
Neothetics, Inc

Completed

Dose-ranging Study (LIPO-102-CL-11)

Abdominal Contour Defects

United States
GlaxoSmithKline

Completed

Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations

Pulmonary Disease, Chronic Obstructive

United States, Canada
GlaxoSmithKline

Completed

A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg BID In Symptomatic Subjects With Asthma

Asthma

United States, Argentina, Canada, Philippines, Brazil
Novartis Pharmaceuticals

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.

Asthma
GlaxoSmithKline

Completed

Pediatric Asthma Study Using Stepwise Treatment With Two Food And Drug Administration Approved Asthma Medications

Asthma

Netherlands
GlaxoSmithKline

Completed

Study Of Asthma In Patients Of African Descent

Asthma

United States
GlaxoSmithKline

Completed

Fluticasone Propionate-salmeterol Combination Adherence in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Arthur F Gelb MD

Completed

Evaluation Inhaled Corticosteroids on Exhaled Nitric Oxide Gas Exchange

COPD

United States
FLUIDDA nv

Completed

Compare the Effects of Seretide® Evohaler and a Generic Salmeterol/Fluticasone Hydrofluoroalkane (HFA) Pressurized Metered-dose Inhaler (pMDI) on Functional Respiratory Imaging Parameters in Asthmatic Patients

Asthma

Belgium
GlaxoSmithKline

Completed

Fall Epidemic Viral Pediatric Study

Asthma

United States
GlaxoSmithKline

Completed

Advair HFA For Chronic Obstructive Pulmonary Disease(COPD)

Pulmonary Disease, Chronic Obstructive

United States
GlaxoSmithKline

Completed

A 3 Way Cross-over Study Evaluating the Effects of ADOAIR Twice Daily Plus Tiotropium Bromide Once Daily Compared With the Individual Treatments of Japanese Subjects (SCO116572)

Pulmonary Disease, Chronic Obstructive

Japan
GlaxoSmithKline

Completed

ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies.

Pulmonary Disease, Chronic Obstructive

United States, Canada
GlaxoSmithKline

Completed

A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma

Asthma

United States, Russian Federation, Canada, Germany, Peru, Australia, Mexico, Chile, Costa Rica, Spain, Poland, Lithuania, Latvia
GlaxoSmithKline

Completed

Study Of Airway Physiology In Adults. SERETIDE DISKUS® Inhaler and FLIXOTIDE® Inhaler Are Trademarks of GSK Croup of Companies.

Asthma

United Kingdom
GlaxoSmithKline

Completed

Study In Airway Physiology In Children SERETIDE DISKUS ® Inhlaer and FLIXOTIDE® Inhaler Are Trademarks of GSK Group of Companies.

Asthma

United Kingdom, New Zealand
University of Dundee

Completed

Fluticasone/Salmeterol (FP/SM) Versus Double the Dose Fluticasone (FP) in Patients With Mild to Moderate Asthma (CLE001)

Asthma

United Kingdom
GlaxoSmithKline

Terminated

ADVAIR DISKUS® (Fluticasone Propionate/Salmeterol) Inhaler Versus SEREVENT DISKUS® (Salmeterol) Inhlaer On Inflammatory Cells And Markers In Chronic Obstructive Pulmonary Disease. ADVAIR DISKUS® and SEREVENT DISKUS® Inhalers Are Trademarks of the GSK Group of Companies.

Pulmonary Disease, Chronic Obstructive

United States
GlaxoSmithKline

Completed

Outcomes for Medicare Asthma Patients Taking Fluticasone Propionate/Salmeterol Xinafoate Combination Versus Inhaled Corticosteroids or Other Combination Therapy

Asthma
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Recruiting

Bioequivalence Study for Fluticasone Propionate 500 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers

Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Pivotal Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence

Greece
Allergy and Asthma Center of El Paso
GlaxoSmithKline

Unknown

Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS)

Asthma

United States
GlaxoSmithKline

Completed

A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise

Bronchospasm | Activity/Exercise Induced Bronchospasm

United States
GlaxoSmithKline

Completed

Seretide Versus Flixotide In Asthmatic Children Not Controlled By Inhaled Corticosteroids

Asthma

Russian Federation, Belgium, Poland, Spain, Denmark, Italy, Sweden, Netherlands, France, Lithuania, Latvia, Norway
GlaxoSmithKline

Terminated

Study Of RV-39 In Patients Who Also Have Asthma

Asthma

United States
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Bioequivalence Study Between Fluticasone and Salmeterol vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade

Bioequivalence

Greece
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and Older

Asthma

United States
GlaxoSmithKline

Completed

Study Of Patients With Allergic Rhinitis And Asthma

Asthma

United States
Novartis

Completed

Investigation of the 24 Hour Forced Expiratory Flow in 1 Second (FEV1) Profile of a Single Dose of Indacaterol/Mometasone Delivered Via the TWISTHALER® Device in Adult Patients With Persistent Asthma

Asthma

Germany, Belgium
The Korean Academy of Tuberculosis and Respiratory...
GlaxoSmithKline

Completed

Clinical Outcomes of Tiotropium Plus Fluticasone Propionate/Salmeterol Compared With Tiotropium for Chronic Obstructive Pulmonary Disease (COPD) in Korea

Chronic Obstructive Pulmonary Disease

Korea, Republic of
Boehringer Ingelheim

Completed

Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Australia, Belgium, Brazil, Bulgaria, China, Denmark, France, Germany, Greece, Hungary, Italy, Netherlands, New Zealand, Philippines, Poland, Russian Federation, South Africa, Spain, Taiwan, Tunisia, Turkey, Ukraine, United Kingdom
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma

Persistent Asthma

United States

3

Subscribe